CDSCO Identifies 330 Drug Samples as Not of Standard Quality in September
Total Views |
New Delhi , October 24 : The Central Drugs Standard Control Organisation (CDSCO) has identified 330 drug samples as Not of Standard Quality (NSQ) during September 2026, according to an official statement released by the organisation.
The monthly testing exercise forms part of the country's broader drug quality monitoring system, which seeks to ensure that medicines available to consumers comply with established standards.
Of the total samples identified, 42 were detected by Central Drugs Laboratories, while State Drugs Testing Laboratories identified 288 samples as not meeting the prescribed quality standards.
According to CDSCO, a drug sample is classified as Not of Standard Quality when it fails to meet one or more specified quality parameters during laboratory testing.
The classification applies to the particular drug products tested by government laboratories. CDSCO clarified that the identification of a sample as NSQ does not automatically raise concerns about other drug products available in the market.
The findings are part of the regulatory mechanism used to monitor the quality of medicines and identify products that do not comply with prescribed standards.
CDSCO stated that the identification of NSQ and spurious medicines is carried out regularly in coordination with state drug regulatory authorities.
The exercise aims to identify medicines that fail to meet the required standards and facilitate their removal from the market, helping safeguard public health.
The collaboration between central and state authorities enables the testing of drug samples through their respective laboratories and supports regulatory action against non-compliant products.
CDSCO, which functions under the Union Ministry of Health and Family Welfare, is responsible for regulating the quality, safety and efficacy of drugs in India, in coordination with state drug control authorities.